Anticoagulation in transradial percutaneous coronary intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Medicine

Background:

• Transradial percutaneous coronary intervention (PCI) offers significant advantages over the transfemoral approach.
• Reduced access site complications and major bleeding are key benefits of the transradial route.
• Anticoagulation choice varies globally, with bivalirudin common in the US and unfractionated heparin used internationally for transradial PCI.

Purpose of the Study:

• To review studies on anticoagulation strategies in transradial PCI.
• To provide a rationale for combining the transradial approach with optimal anticoagulation.
• To highlight the reduction of both access site and non-access site bleeding.

Main Methods:

• Literature review of studies evaluating anticoagulation in transradial PCI.
• Analysis of current anticoagulation practices in different regions.
• Synthesis of evidence supporting combined approaches for bleeding reduction.

Main Results:

• Transradial PCI is linked to lower rates of access site issues and major bleeding compared to transfemoral.
• Specific anticoagulants like bivalirudin are favored in certain regions for transradial PCI.
• Emerging evidence suggests benefits in high-risk bleeding scenarios, including acute myocardial infarction.

Conclusions:

• The transradial approach is a valuable strategy for coronary interventions, particularly for reducing bleeding.
• Tailoring anticoagulant therapy to the transradial approach is crucial for optimizing patient outcomes.
• Combining the transradial approach with appropriate anticoagulation offers a synergistic effect in minimizing bleeding complications.